An AT2R agonist comprising an amino acid sequence that corresponds to the formula: A1-A2-A3-A4-A5-A6 wherein: A1 is Lys, A2 is Pro, A3 is Leu, A4 is Lys, A5 is Pro, and A6 is Trp, for use in binding and activating an AT2R protein or inhibiting an AT1R protein in a cell expressing the AT2R protein for use in the treatment of: (i) a metabolic disorder or cancer, optionally wherein the metabolic disorder is selected from cardiovascular and renal disease, or type 2 diabetes; or (ii) a condition characterized by under expression or activation of the AT2R or insufficient activity or production of a downstream effector of AT2R selected from the group consisting of MTOR, NHE6, ErbB3, Nitric Oxide Synthase, MCL-1 and prostaglandin 12-IP; wherein said condition is selected from the group consisting of diabetes, cancer involving dysfunction of ErbB3 and hypertension; or (iii) a neurological condition selected from the group consisting of autism, ALS, Alzheimer's, Parkinson's, muscular dystrophy and Huntington's Disease; or (iv) an injury selected from the group consisting of spinal cord injury, traumatic brain injury, and brain lesions; or (v) a condition characterized by the dysregulation of the Renin-Angiotensin System, selected from the group consisting of hypertension, nephropathy, renal disease, cardiovascular disease and metabolic syndrome; or (vi) a condition characterized by over activation of the AT1R, selected from the group consisting of nephropathy, hypertension and metabolic syndrome; or (vii) a condition characterized by high blood sugar such as diabetes and metabolic syndrome. A1 is Lys, A2 is Pro, A3 is Leu, A4 is Lys, A5 is Pro, and A6 is Trp, for use in binding and activating an AT2R protein or inhibiting an AT1R protein in a cell expressing the AT2R protein for use in the treatment of: (i) a metabolic disorder or cancer, optionally wherein the metabolic disorder is selected from cardiovascular and renal disease, or type 2 diabetes; or (ii) a condition characterized by under expression or activation of the AT2R or insufficient activity or production of a downstream effector of AT2R selected from the group consisting of MTOR, NHE6, ErbB3, Nitric Oxide Synthase, MCL-1 and prostaglandin 12-IP; wherein said condition is selected from the group consisting of diabetes, cancer involving dysfunction of ErbB3 and hypertension; or (iii) a neurological condition selected from the group consisting of autism, ALS, Alzheimer's, Parkinson's, muscular dystrophy and Huntington's Disease; or (iv) an injury selected from the group consisting of spinal cord injury, traumatic brain injury, and brain lesions; or (v) a condition characterized by the dysregulation of the Renin-Angiotensin System, selected from the group consisting of hypertension, nephropathy, renal disease, cardiovascular disease and metabolic syndrome; or (vi) a condition characterized by over activation of the AT1R, selected from the group consisting of nephropathy, hypertension and metabolic syndrome; or (vii) a condition characterized by high blood sugar such as diabetes and metabolic syndrome. (i) a metabolic disorder or cancer, optionally wherein the metabolic disorder is selected from cardiovascular and renal disease, or type 2 diabetes; or (ii) a condition characterized by under expression or activation of the AT2R or insufficient activity or production of a downstream effector of AT2R selected from the group consisting of MTOR, NHE6, ErbB3, Nitric Oxide Synthase, MCL-1 and prostaglandin 12-IP; wherein said condition is selected from the group consisting of diabetes, cancer involving dysfunction of ErbB3 and hypertension; or (iii) a neurological condition selected from the group consisting of autism, ALS, Alzheimer's, Parkinson's, muscular dystrophy and Huntington's Disease; or (iv) an injury selected from the group consisting of spinal cord injury, traumatic brain injury, and brain lesions; or (v) a condition characterized by the dysregulation of the Renin-Angiotensin System, selected from the group consisting of hypertension, nephropathy, renal disease, cardiovascular disease and metabolic syndrome; or (vi) a condition characterized by over activation of the AT1R, selected from the group consisting of nephropathy, hypertension and metabolic syndrome; or (vii) a condition characterized by high blood sugar such as diabetes and metabolic syndrome.